SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kaminski, M. S. Articles by Wahl, R. L. Search for Related Content PubMed PubMed Citation Articles by Kaminski, M. S. Articles by Wahl, R. L. Related Collections Neoplasia Immunotherapy Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 August 2000, Vol. 96, No. 4, pp. 1259-1266 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Mark S. Kaminski, Judith Estes, Kenneth R. Zasadny, Isaac R. Francis, Charles W. Ross, Melissa Tuck, Denise Regan, Susan Fisher, Jeanne Gutierrez, Stewart Kroll, Robert Stagg, George Tidmarsh, and Richard L. Wahl From the Divisions of Hematology/Oncology and Nuclear Medicine, Departments of Internal Medicine, Radiology and Pathology, University of Michigan, Ann Arbor, MI; and Coulter Pharmaceutical, Inc, South San Francisco, CA. CD20-targeted radioimmunotherapy is a promising new treatment for B-cell non-Hodgkin lymphoma (NHL). We now provide updated and long-term data on 59 chemotherapy-relapsed/refractory patients treated with iodine 131I tositumomab in a phase I/II single-center study. Fifty-three patients received individualized therapeutic doses, delivering a specified total-body radiation dose (TBD) based on the clearance rate of a preceding dosimetric dose. Six patients received dosimetric doses only. Dose-escalations of TBD were conducted separately in patients who had or had not undergone a prior autologous stem cell transplant (ASCT) until a nonmyeloablative maximally tolerated TBD was established (non-ASCT = 75 cGy, post-ASCT = 45 cGy). Fourteen additional non-ASCT patients were treated with 75 cGy. Unlabeled antibody was given prior to labeled dosimetric and therapeutic doses to improve biodistribution. Forty-two (71%) of 59 patients responded; 20 (34%) had complete responses (CR). Thirty-five (83%) of 42 with low-grade or transformed NHL responded versus 7 (41%) of 17 with de novo intermediate-grade NHL (P = .005). For all 42 responders, the median progression-free survival was 12 months, 20.3 for those with CR. Seven patients remain in CR 3 to 5.7 years. Sixteen patients were re-treated after progression; 9 responded and 5 had a CR. Reversible hematologic toxicity was dose limiting. Only 10 patients (17%) had human anti-mouse antibodies detected. Long-term, 5 patients developed elevated thyroid-stimulating hormone levels, 5 were diagnosed with myelodysplasia and 3 with solid tumors. A single, well-tolerated treatment with iodine 131I tositumomab can, therefore, produce frequent and durable responses in NHL, especially low-grade or transformed NHL. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K Hodby and P A Fields Management of lymphoma in pregnancy Obstet Med, June 1, 2009; 2(2): 46 - 51. [Abstract] [Full Text] [PDF] T. M. Illidge, M. Bayne, N. S. Brown, S. Chilton, M. S. Cragg, M. J. Glennie, Y. Du, V. Lewington, J. Smart, J. Thom, et al. Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy Blood, February 12, 2009; 113(7): 1412 - 1421. [Abstract] [Full Text] [PDF] H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl 18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy J. Nucl. Med., January 1, 2009; 50(1): 8 - 17. [Abstract] [Full Text] [PDF] M. J. Bishton, M. F. Leahy, R. J. Hicks, J. H. Turner, A. D. McQuillan, and J. F. Seymour Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab Ann. Onc., September 1, 2008; 19(9): 1629 - 1633. [Abstract] [Full Text] [PDF] B. D. Cheson and J. P. Leonard Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626. [Full Text] [PDF] F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma Oncologist, June 1, 2008; 13(6): 657 - 667. [Abstract] [Full Text] [PDF] H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice J. Nucl. Med., November 1, 2007; 48(11): 1767 - 1776. [Abstract] [Full Text] [PDF] D. J. Green, J. M. Pagel, A. Pantelias, N. Hedin, Y. Lin, D. S. Wilbur, A. Gopal, D. K. Hamlin, and O. W. Press Pretargeted Radioimmunotherapy for B-Cell Lymphomas Clin. Cancer Res., September 15, 2007; 13(18): 5598s - 5603s. [Abstract] [Full Text] [PDF] J. Dahle, J. Borrebaek, T. J. Jonasdottir, A. K. Hjelmerud, K. B. Melhus, O. S. Bruland, O. W. Press, and R. H. Larsen Targeted cancer therapy with a novel low-dose rate {alpha}-emitting radioimmunoconjugate Blood, September 15, 2007; 110(6): 2049 - 2056. [Abstract] [Full Text] [PDF] J. M. Pagel, A. Pantelias, N. Hedin, S. Wilbur, L. Saganic, Y. Lin, D. Axworthy, D. K. Hamlin, D. S. Wilbur, A. K. Gopal, et al. Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas Cancer Res., June 15, 2007; 67(12): 5921 - 5928. [Abstract] [Full Text] [PDF] A. Pantelias, J. M. Pagel, N. Hedin, L. Saganic, S. Wilbur, D. K. Hamlin, D. S. Wilbur, Y. Lin, D. Stone, D. Axworthy, et al. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas Blood, June 1, 2007; 109(11): 4980 - 4987. [Abstract] [Full Text] [PDF] M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 PNAS, May 15, 2007; 104(20): 8444 - 8448. [Abstract] [Full Text] [PDF] H. Song, Y. Du, G. Sgouros, A. Prideaux, E. Frey, and R. L. Wahl Therapeutic Potential of 90Y- and 131I-Labeled Anti-CD20 Monoclonal Antibody in Treating Non-Hodgkin's Lymphoma with Pulmonary Involvement: A Monte Carlo-Based Dosimetric Analysis J. Nucl. Med., January 1, 2007; 48(1): 150 - 157. [Abstract] [Full Text] [PDF] M. F. Leahy, J. F. Seymour, R. J. Hicks, and J. H. Turner Multicenter Phase II Clinical Study of Iodine-131-Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma J. Clin. Oncol., September 20, 2006; 24(27): 4418 - 4425. [Abstract] [Full Text] [PDF] O. W. Press, J. M. Unger, R. M. Braziel, D. G. Maloney, T. P. Miller, M. LeBlanc, and R. I. Fisher Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911 J. Clin. Oncol., September 1, 2006; 24(25): 4143 - 4149. [Abstract] [Full Text] [PDF] M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, S. Yu, H.-S. Kim, C. K. Goldman, C. H. Paik, et al. The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the {alpha}-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia Cancer Res., August 15, 2006; 66(16): 8227 - 8232. [Abstract] [Full Text] [PDF] J. M. Pagel, Y. Lin, N. Hedin, A. Pantelias, D. Axworthy, D. Stone, D. K. Hamlin, D. S. Wilbur, and O. W. Press Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas Blood, July 1, 2006; 108(1): 328 - 336. [Abstract] [Full Text] [PDF] D. A. Reardon, J. A. Quinn, G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. M. Provenzale, et al. Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results J. Nucl. Med., June 1, 2006; 47(6): 912 - 918. [Abstract] [Full Text] [PDF] R. M. Reilly Radioimmunotherapy of Solid Tumors: The Promise of Pretargeting Strategies Using Bispecific Antibodies and Radiolabeled Haptens J. Nucl. Med., February 1, 2006; 47(2): 196 - 199. [Full Text] [PDF] S. M. Glaser, I. E. Hughes, J. R. Hopp, K. Hathaway, D. Perret, and M. E. Reff Novel Antibody Hinge Regions for Efficient Production of CH2 Domain-deleted Antibodies J. Biol. Chem., December 16, 2005; 280(50): 41494 - 41503. [Abstract] [Full Text] [PDF] W. Hiddemann, M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder, R. Schmits, M. Reiser, B. Metzner, H. Harder, S. Hegewisch-Becker, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood, December 1, 2005; 106(12): 3725 - 3732. [Abstract] [Full Text] [PDF] R. I. Fisher, M. LeBlanc, O. W. Press, D. G. Maloney, J. M. Unger, and T. P. Miller New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma J. Clin. Oncol., November 20, 2005; 23(33): 8447 - 8452. [Abstract] [Full Text] [PDF] M. S. Kaminski, J. A. Radford, S. A. Gregory, J. P. Leonard, S. J. Knox, S. Kroll, and R. L. Wahl Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab J. Clin. Oncol., November 1, 2005; 23(31): 7985 - 7993. [Abstract] [Full Text] [PDF] R. I. Fisher, M. S. Kaminski, R. L. Wahl, S. J. Knox, A. D. Zelenetz, J. M. Vose, J. P. Leonard, S. Kroll, S. J. Goldsmith, and M. Coleman Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin's Lymphomas J. Clin. Oncol., October 20, 2005; 23(30): 7565 - 7573. [Abstract] [Full Text] [PDF] I. Burvenich, S. Schoonooghe, B. Cornelissen, P. Blanckaert, E. Coene, C. Cuvelier, N. Mertens, and G. Slegers In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131-Labeled Monoclonal Antibody 14C5 in a Non-Small Cell Lung Cancer and Colon Carcinoma Model Clin. Cancer Res., October 15, 2005; 11(20): 7288 - 7296. [Abstract] [Full Text] [PDF] S. A. Jacobs, N. Vidnovic, J. Joyce, B. McCook, F. Torok, and N. Avril Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients with Prior Myeloablative Chemotherapy Clin. Cancer Res., October 1, 2005; 11(19): 7146s - 7150s. [Abstract] [Full Text] [PDF] A. H. Brouwers, P. F.A. Mulders, P. H.M. de Mulder, W. J.M. van den Broek, W. C.A.M. Buijs, C. Mala, F. B.M. Joosten, E. Oosterwijk, O. C. Boerman, F. H.M. Corstens, et al. Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma J. Clin. Oncol., September 20, 2005; 23(27): 6540 - 6548. [Abstract] [Full Text] [PDF] W. Hiddemann, C. Buske, M. Dreyling, O. Weigert, G. Lenz, R. Forstpointner, C. Nickenig, and M. Unterhalt Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives J. Clin. Oncol., September 10, 2005; 23(26): 6394 - 6399. [Abstract] [Full Text] [PDF] C. Nabhan Should We Transplant Indolent Lymphoma? J. Clin. Oncol., September 1, 2005; 23(25): 6263 - 6264. [Full Text] [PDF] J. P. Leonard, M. Coleman, L. Kostakoglu, A. Chadburn, E. Cesarman, R. R. Furman, M. W. Schuster, R. Niesvizky, D. Muss, J. Fiore, et al. Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma J. Clin. Oncol., August 20, 2005; 23(24): 5696 - 5704. [Abstract] [Full Text] [PDF] A. V. Rao, G. Akabani, and D. A. Rizzieri Radioimmunotherapy for Non-Hodgkin's Lymphoma Clin. Med. Res., August 1, 2005; 3(3): 157 - 165. [Abstract] [Full Text] [PDF] S. M. Ansell and J. Armitage Non-Hodgkin Lymphoma: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2005; 80(8): 1087 - 1097. [Abstract] [PDF] O. Linden, C. Hindorf, E. Cavallin-Stahl, W. A. Wegener, D. M. Goldenberg, H. Horne, T. Ohlsson, L. Stenberg, S.-E. Strand, and J. Tennvall Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab Clin. Cancer Res., July 15, 2005; 11(14): 5215 - 5222. [Abstract] [Full Text] [PDF] S. Vallabhajosula, I. Kuji, K. A. Hamacher, S. Konishi, L. Kostakoglu, P. A. Kothari, M. I. Milowski, D. M. Nanus, N. H. Bander, and S. J. Goldsmith Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu? J. Nucl. Med., April 1, 2005; 46(4): 634 - 641. [Abstract] [Full Text] [PDF] M. S. Kaminski, M. Tuck, J. Estes, A. Kolstad, C. W. Ross, K. Zasadny, D. Regan, P. Kison, S. Fisher, S. Kroll, et al. 131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma N. Engl. J. Med., February 3, 2005; 352(5): 441 - 449. [Abstract] [Full Text] [PDF] S. J. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas, D. Podoloff, and M. Goris Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab J. Clin. Oncol., February 1, 2005; 23(4): 712 - 719. [Abstract] [Full Text] [PDF] R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF] R. L. Wahl Tositumomab and 131I Therapy in Non-Hodgkin's Lymphoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 128S - 140S. [Abstract] [Full Text] [PDF] L. S. Shahied, Y. Tang, R. K. Alpaugh, R. Somer, D. Greenspon, and L. M. Weiner Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format J. Biol. Chem., December 24, 2004; 279(52): 53907 - 53914. [Abstract] [Full Text] [PDF] S. A. Jacobs, B. McCook, F. Torok, N. Avril, N. Vidnovic, J. Joyce, and A. Molina Evaluation of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin(R)) in Patients with Non-Hodgkin's Lymphoma (NHL) Having Previously Received Autologous Stem Cell Transplant (ASCT). Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 5238 - 5238. [Abstract] R. Forstpointner, M. Dreyling, R. Repp, S. Hermann, A. Hanel, B. Metzner, C. Pott, F. Hartmann, F. Rothmann, R. Rohrberg, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood, November 15, 2004; 104(10): 3064 - 3071. [Abstract] [Full Text] [PDF] S. Hallmeyer and D. Peace Integrative Tumor Board: Recurrent Lymphoma Integr Cancer Ther, September 1, 2004; 3(3): 239 - 243. [PDF] D. A. Rizzieri, G. Akabani, M. R. Zalutsky, R. E. Coleman, S. D. Metzler, J. E. Bowsher, B. Toaso, E. Anderson, A. Lagoo, S. Clayton, et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma Blood, August 1, 2004; 104(3): 642 - 648. [Abstract] [Full Text] [PDF] A.J. Davies, A.Z.S. Rohatiner, S. Howell, K.E. Britton, S.E. Owens, I.N. Micallef, D.P. Deakin, B.M. Carrington, J.A. Lawrance, S. Vinnicombe, et al. Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., April 15, 2004; 22(8): 1469 - 1479. [Abstract] [Full Text] [PDF] J. M. Vose Bexxar(R): Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma Oncologist, April 1, 2004; 9(2): 160 - 172. [Abstract] [Full Text] [PDF] S. Knop, A. Jakob, L. Kanz, H. Hebart, R. Bares, and B. Dohmen 186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma Blood, February 1, 2004; 103(3): 1175 - 1175. [Full Text] [PDF] R. M. Sharkey, A. Brenner, J. Burton, G. Hajjar, S. P. Toder, A. Alavi, A. Matthies, D. E. Tsai, S. J. Schuster, E. A. Stadtmauer, et al. Radioimmunotherapy of Non-Hodgkin's Lymphoma with 90Y-DOTA Humanized Anti-CD22 IgG (90Y-Epratuzumab): Do Tumor Targeting and Dosimetry Predict Therapeutic Response? J. Nucl. Med., December 1, 2003; 44(12): 2000 - 2018. [Abstract] [Full Text] [PDF] P. K. E. Borjesson, E. J. Postema, J. C. Roos, D. R. Colnot, H. A. M. Marres, M. H. van Schie, G. Stehle, R. de Bree, G. B. Snow, W. J. G. Oyen, et al. Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., September 1, 2003; 9(10): 3961S - 3972. [Abstract] [Full Text] [PDF] B. M. Bradt, S. J. DeNardo, G. R. Mirick, and G. L. DeNardo Documentation of Idiotypic Cascade after Lym-1 Radioimmunotherapy in a Patient with Non-Hodgkin's Lymphoma: Basis for Extended Survival? Clin. Cancer Res., September 1, 2003; 9(10): 4007S - 4012. [Abstract] [Full Text] [PDF] G. L. DeNardo, G. R. Mirick, L. A. Kroger, B. M. Bradt, K. R. Lamborn, and S. J. DeNardo Characterization of Human IgG Antimouse Antibody in Patients with B-Cell Malignancies Clin. Cancer Res., September 1, 2003; 9(10): 4013S - 4021. [Abstract] [Full Text] [PDF] O. W. Press, J. M. Unger, R. M. Braziel, D. G. Maloney, T. P. Miller, M. LeBlanc, E. R. Gaynor, S. E. Rivkin, and R. I. Fisher A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911 Blood, September 1, 2003; 102(5): 1606 - 1612. [Abstract] [Full Text] [PDF] E. J. Postema, W. J.G. Oyen, O. C. Boerman, and F. H.M. Corstens Administration Guidelines for Radioimmunotherapy of Non-Hodgkin's Lymphoma with 90Y-Labeled Anti-CD20 Monoclonal Antibody J. Nucl. Med., May 1, 2003; 44(5): 853 - 853. [Full Text] [PDF] J. M. Pagel, N. Hedin, K. Subbiah, D. Meyer, R. Mallet, D. Axworthy, L. J. Theodore, D. S. Wilbur, D. C. Matthews, and O. W. Press Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas Blood, March 15, 2003; 101(6): 2340 - 2348. [Abstract] [Full Text] [PDF] T. A. Riccobene, R. C. Miceli, C. Lincoln, Y. Knight, J. Meadows, M. G. Stabin, and C. Sung Rapid and Specific Targeting of 125I-Labeled B Lymphocyte Stimulator to Lymphoid Tissues and B Cell Tumors in Mice J. Nucl. Med., March 1, 2003; 44(3): 422 - 433. [Abstract] [Full Text] [PDF] D. J. Buchsbaum and A. F. LoBuglio Targeting of 125I-Labeled B Lymphocyte Stimulator J. Nucl. Med., March 1, 2003; 44(3): 434 - 436. [Full Text] [PDF] K. Subbiah, D. K. Hamlin, J. M. Pagel, D. S. Wilbur, D. L. Meyer, D. B. Axworthy, R. W. Mallett, L. J. Theodore, P. S. Stayton, and O. W. Press Comparison of Immunoscintigraphy, Efficacy, and Toxicity of Conventional and Pretargeted Radioimmunotherapy in CD20-Expressing Human Lymphoma Xenografts J. Nucl. Med., March 1, 2003; 44(3): 437 - 445. [Abstract] [Full Text] [PDF] J. O. Armitage, P. P. Carbone, J. M. Connors, A. Levine, J. M. Bennett, and S. Kroll Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin's Lymphoma Patients J. Clin. Oncol., March 1, 2003; 21(5): 897 - 906. [Abstract] [Full Text] [PDF] G. Sgouros, S. Squeri, A. M. Ballangrud, K. S. Kolbert, J. B. Teitcher, K. S. Panageas, R. D. Finn, C. R. Divgi, S. M. Larson, and A. D. Zelenetz Patient-Specific, 3-Dimensional Dosimetry in Non-Hodgkin's Lymphoma Patients Treated with 131I-anti-B1 Antibody: Assessment of Tumor Dose-Response J. Nucl. Med., February 1, 2003; 44(2): 260 - 268. [Abstract] [Full Text] [PDF] M. S. Cragg, S. M. Morgan, H. T. C. Chan, B. P. Morgan, A. V. Filatov, P. W. M. Johnson, R. R. French, and M. J. Glennie Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts Blood, February 1, 2003; 101(3): 1045 - 1052. [Abstract] [Full Text] [PDF] B. D. Cheson Radioimmunotherapy of non-Hodgkin lymphomas Blood, January 15, 2003; 101(2): 391 - 398. [Abstract] [Full Text] [PDF] G. L. Griffiths, S. V. Govindan, R. M. Sharkey, D. R. Fisher, and D. M. Goldenberg 90Y-DOTA-hLL2: An Agent for Radioimmunotherapy of Non-Hodgkin's Lymphoma J. Nucl. Med., January 1, 2003; 44(1): 77 - 84. [Abstract] [Full Text] [PDF] M. E. Juweid Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice J. Nucl. Med., November 1, 2002; 43(11): 1507 - 1529. [Abstract] [Full Text] [PDF] D. R. Colnot, G. J. Ossenkoppele, J. C. Roos, J. J. Quak, R. de Bree, P. K. Borjesson, P. C. Huijgens, G. B. Snow, and G. A. M. S. van Dongen Reinfusion of Unprocessed, Granulocyte Colony-stimulating Factor-stimulated Whole Blood Allows Dose Escalation of 186Relabeled Chimeric Monoclonal Antibody U36 Radioimmunotherapy in a Phase I Dose Escalation Study Clin. Cancer Res., November 1, 2002; 8(11): 3401 - 3406. [Abstract] [Full Text] [PDF] D. W. Seldin Techniques for Using Bexxar for the Treatment of Non-Hodgkin's Lymphoma* J. Nucl. Med. Technol., September 1, 2002; 30(3): 109 - 114. [Abstract] [Full Text] [PDF] R. O. Dillman Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma J. Clin. Oncol., August 15, 2002; 20(16): 3545 - 3557. [Full Text] [PDF] M. Hunault-Berger, N. Ifrah, and P. Solal-Celigny Intensive therapies in follicular non-Hodgkin lymphomas Blood, July 30, 2002; 100(4): 1141 - 1152. [Full Text] [PDF] J. G. Jurcic, S. M. Larson, G. Sgouros, M. R. McDevitt, R. D. Finn, C. R. Divgi, A. M. Ballangrud, K. A. Hamacher, D. Ma, J. L. Humm, et al. Targeted alpha particle immunotherapy for myeloid leukemia Blood, July 30, 2002; 100(4): 1233 - 1239. [Abstract] [Full Text] [PDF] P. McLaughlin Progress and Promise in the Treatment of Indolent Lymphomas Oncologist, June 1, 2002; 7(3): 217 - 225. [Abstract] [Full Text] [PDF] G. A. Wiseman, L. I. Gordon, P. S. Multani, T. E. Witzig, S. Spies, N. L. Bartlett, R. J. Schilder, J. L. Murray, M. Saleh, R. S. Allen, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial Blood, May 29, 2002; 99(12): 4336 - 4342. [Abstract] [Full Text] [PDF] T. E. Witzig, L. I. Gordon, F. Cabanillas, M. S. Czuczman, C. Emmanouilides, R. Joyce, B. L. Pohlman, N. L. Bartlett, G. A. Wiseman, N. Padre, et al. Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., May 15, 2002; 20(10): 2453 - 2463. [Abstract] [Full Text] [PDF] D. M. Goldenberg Targeted Therapy of Cancer with Radiolabeled Antibodies J. Nucl. Med., May 1, 2002; 43(5): 693 - 713. [Abstract] [Full Text] [PDF] J. A. Siegel, S. Kroll, D. Regan, M. S. Kaminski, and R. L. Wahl A Practical Methodology for Patient Release After Tositumomab and 131I-Tositumomab Therapy J. Nucl. Med., March 1, 2002; 43(3): 354 - 363. [Abstract] [Full Text] [PDF] H. Kobayashi, K. Shirakawa, S. Kawamoto, T. Saga, N. Sato, A. Hiraga, I. Watanabe, Y. Heike, K. Togashi, J. Konishi, et al. Rapid Accumulation and Internalization of Radiolabeled Herceptin in an Inflammatory Breast Cancer Xenograft with Vasculogenic Mimicry Predicted by the Contrast-enhanced Dynamic MRI with the Macromolecular Contrast Agent G6-(1B4M-Gd)256 Cancer Res., February 1, 2002; 62(3): 860 - 866. [Abstract] [Full Text] [PDF] J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma Hematology, January 1, 2002; 2002(1): 241 - 262. [Abstract] [Full Text] O. W. Press, M. Corcoran, K. Subbiah, D. K. Hamlin, D. S. Wilbur, T. Johnson, L. Theodore, E. Yau, R. Mallett, D. L. Meyer, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts Blood, October 15, 2001; 98(8): 2535 - 2543. [Abstract] [Full Text] [PDF] B. D. Cheson Some Like It Hot! J. Clin. Oncol., October 1, 2001; 19(19): 3908 - 3911. [Full Text] M. S. Kaminski, A. D. Zelenetz, O. W. Press, M. Saleh, J. Leonard, L. Fehrenbacher, T. A. Lister, R. J. Stagg, G. F. Tidmarsh, S. Kroll, et al. Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas J. Clin. Oncol., October 1, 2001; 19(19): 3918 - 3928. [Abstract] [Full Text] S. L. McCune, J. P. Gockerman, and D. A. Rizzieri Monoclonal Antibody Therapy in the Treatment of Non-Hodgkin Lymphoma JAMA, September 12, 2001; 286(10): 1149 - 1152. [Full Text] [PDF] O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman Immunotherapy of Non-Hodgkin's Lymphomas Hematology, January 1, 2001; 2001(1): 221 - 240. [Abstract] [Full Text] [PDF]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020